Fujikawa K, Mogi Y, Ito K, Tsushima N, Saito T, Ishigaki S, Watanabe N, Kohgo Y, Mikami T, Niitsu Y
Dept. of Internal Medicine (Section 4), Sapporo Medical College.
Gan To Kagaku Ryoho. 1991 Feb;18(2):287-91.
A 63-year-old male with refractory anemia with excess of blasts (RAEB) and hypoplastic marrow was treated with K-18 (240 mg/day P.O.). On admission, peripheral blood revealed pancytopenia. Bone marrow specimen revealed severe hypocellularity with 18.9% of the blast cells. Ten months later, the blast cells in the bone marrow decreased to 3.8%, and complete remission (CR) was obtained. CR was eight weeks. Duration of response (CR + PR) continued for about eight months. K-18 is an antitumor agent with minimal side effects, and seems to be effective for RAEB with hypoplastic marrow.
一名63岁男性，患有伴原始细胞增多的难治性贫血（RAEB）且骨髓增生低下，接受了K-18治疗（口服，每日240毫克）。入院时，外周血显示全血细胞减少。骨髓标本显示严重的细胞减少，原始细胞占18.9%。十个月后，骨髓中的原始细胞降至3.8%，达到完全缓解（CR）。CR持续了八周。缓解持续时间（CR + PR）约为八个月。K-18是一种副作用极小的抗肿瘤药物，似乎对伴有骨髓增生低下的RAEB有效。
